Bezafibrate maintenance therapy in patients with advanced chronic hepatitis C

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 5, 2013, Pages 594-600

  Knop, Viola ^a,c   Bergk, Alexandra ^a   Schlosser, Beate ^a,b   Thieringer, Juliane ^a,d   Van Bömmel, Florian ^a,e   Frost, Nikolaj ^a   Kintscher, Ulrich ^f   Berg, Thomas ^a,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Vivantes Auguste Viktoria Klinikum   (Germany)

^d AGAPLESION MARKUS KRANKENHAUS   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

bezafibrate; chronic hepatitis C; maintenance therapy; peroxisome proliferator activated receptor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BEZAFIBRATE; GAMMA GLUTAMYLTRANSFERASE; GAMMA INTERFERON; INTERLEUKIN 6; PEGINTERFERON; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LEG CRAMP; LIVER CELL CARCINOMA; MAINTENANCE THERAPY; MALE; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIDE EFFECT; THROMBOCYTE; TREATMENT DURATION; VERTIGO;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; BEZAFIBRATE; BIOLOGICAL MARKERS; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PPAR GAMMA; TREATMENT OUTCOME;

EID: 84876417355     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32835cc878     Document Type: Article

References (43)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567. (Pubitemid 41196755)
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142:1264-1273.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-980.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, SHiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
5. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140:346-355.
6. Di BisceglieAM,ShiffmanML, EversonGT, Lindsay KL, Everhart JE,Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359:2429-2441.
7. Sun HY, Lin CC, Lee JC, Wang SW, Cheng PN, Wu IC, et al. Very lowdensity lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III. Gut 2012 [Epub ahead of print].
8. Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, et al. Characterization of low- and very-low-density hepatitis C virus RNAcontaining particles. J Virol 2002; 76:6919-6928. (Pubitemid 41246207)
9. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96:14766-14771.
10. Dao Thi VL, Dreux M, Cosset FL. Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralization. Expert Rev Mol Med 2011; 13:e13.
11. Meredith LW,Wilson GK, Fletcher NF, McKeating JA. Hepatitis C virus entry: beyond receptors. Rev Med Virol 2012; 22:182-193.
12. Barth H, Schnober EK, Neumann-Haefelin C, Thumann C, Zeisel MB, Diepolder HM, et al. Scavenger receptor Class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J Virol 2008; 82:3466-3479. (Pubitemid 351429922)
13. Burlone ME, Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol 2009; 90:1055-1070.
14. Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K. Study of effectiveness of bezafibrate in the treatment of chronic hepatitis C. Am J Gastroenterol 2001; 96:1659-1660. (Pubitemid 32455123)
15. Fujita N, Kaito M, Tanaka H, Horiike S, Adachi Y. Reduction of serum HCV RNA titer by bezafibrate therapy in patients with chronic hepatitis C. Am J Gastroenterol 2004; 99:2280. (Pubitemid 39524721)
16. Fujita N, Kaito M, Kai M, Sugimoto R, Tanaka H, Horiike S, et al. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. J Viral Hepat 2006; 13:441-448.
17. Mandard S, Müller M, Kersten S. Peroxisome proliferator-activated receptor a target genes. Cell Mol Life Sci 2004; 61:393-416. (Pubitemid 38316578)
18. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98:2088-2093. (Pubitemid 28512236)
19. Lee JY, Hashizaki H, Goto T, Sakamoto T, Takahashi N, Kawada T. Activation of peroxisome proliferator-activated receptor-a enhances fatty acid oxidation in human adipocytes. Biochem Biophys Res Commun 2011; 407: 818-822.
20. Mimo C, Shaul PW. Novel biological functions of high-density lipoprotein cholesterol. Circ Res 2012; 111:1079-1090.
21. Inoue I, Takahashi K, Katayama S, Akabane S, Negishi K, Suzuki M, et al. Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance. Diabetes Res Clin Pract 1994; 25:199-205. (Pubitemid 24336899)
22. Mikhailides DP, Mathur S, Barradas MA, Dandona P. Bezafibrate retard in type II diabetic patients: effect on hemostasis and glucose homeostasis. J Cardiovasc Pharmacol 1990; 16 (Suppl 9):26-29.
23. Chen X, Matthews J, Zhou L, Pelton P, Liang Y, Xu J, et al. Improvement of dyslipidemia, insulin sensitivity and energy balance by a peroxisome proliferator-activated receptor alpha agonist. Metabolism 2008; 57: 1516-1525.
24. Devcand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPRAa-leukotriene B4 pathway to inflammation control. Nature 1996; 384:39-43.
25. Staels B, Koeni W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic small muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 1998; 393:790-793. (Pubitemid 28299490)
26. Erol A. PPARα activators may be good candidates as antiaging agents. Med Hypotheses 2005; 65:35-38.
27. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526. (Pubitemid 36919874)
28. Scheuer PJ. Classification of viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-373.
29. Patterson AD, Shah YM, Matsubara T, Krausz KW, Gonzalez FJ. PPARα-dependent induction of uncoupling protein 2 protects against acetaminophen-induced liver toxicity. Hepatology 2012; 56:281-290.
30. Bader T, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008; 103:1383-1389. (Pubitemid 351813920)
31. Ye J,Wang C, Sumpter R, Brown MS, Goldstein JL, Gale M, et al. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA 2003; 26:15865-15870. (Pubitemid 38021081)
32. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad sci USA 2005; 7:2561-2566. (Pubitemid 40279416)
33. Yano K, Kato H, Morita S, Takahara O, Ishibashi H, Furukawa R, et al. Is bezafibrate histologically effective for primary biliary cirrhosis? Am J Gastroenterol 2002; 97:1075-1077. (Pubitemid 34408290)
34. Kurihara T, Maeda A, Shigemoto M, Yamashita K, Hashimoto E. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. Am J Gastroenterol 2002; 97:212-214. (Pubitemid 34059800)
35. Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, et al. Fibrate and statin synergistically increase the transcriptional activities of PPARαlpha/ RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun 2002; 290:131-139. (Pubitemid 34694475)
36. Videla LA. Liver NF-kB and AP-1 activation and PPAR-a expression are negatively correlated in obese patients: pro-inflammatory implications. Clin Nutr 2010; 29:667-668.
37. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431:461-466. (Pubitemid 39329586)
38. Chang KM, Thimme R, Melpolder JJ, Oldach D, Pemberton J, Moorhead-Loudis J, et al. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 2001; 33:267-276. (Pubitemid 32016910)
39. Neumann-Haefelin C, Thimme R. Success and failure of virus-specific T cell responses in hepatitis C virus infection. Dig Dis 2011; 29:416-422.
40. Marx N, Kehrle B, Kohlhammer K, Grüb M, Koenig W, Hombach V, et al. PPAR activators as anti-inflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002; 90:703-710. (Pubitemid 34640890)
41. Sarobe P, Lasarte JJ, Casares N, Lopez-Diaz de Cerio A, Baixeras E, Labarga P, et al. Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol 2002; 76:5062-5070. (Pubitemid 34441711)
42. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman DJ, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998; 188:2205-2213. (Pubitemid 29028493)
43. Ulsenheimer A, Gerlach JT, Gruener NH, Jung MC, Schirren CA, Schraut W, et al. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology 2003; 37:1189-1198. (Pubitemid 36538697)